Drug Trial Radar · NCT03034915
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Mar 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,696
Actual
Start
Jun 16, 2017
Primary completion
Jun 18, 2018
Study completion Jun 18, 2018
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
COPD is characterized by an airflow limitation, which is not fully reversible, usually progressive and accompanied by chronic cough, sputum production and dyspnea, which can be a major cause of disability and anxiety associated with the disease. In addition, COPD is associated with poor health-related quality of life (HRQoL). Pharmacologic therapy is used to improve lung function, reduce symptoms, reduce the frequency and severity of exacerbations, and also to improve health status and exercise tolerance. This is a multi-center, randomized, double blind, double dummy, 3-arm parallel group study to compare umeclidinium/vilanterol (62.5/25 microgram \[mcg\], once daily), umeclidinium (62.5 mcg, once daily), and salmeterol (50 mg, twice daily) in male and female subjects with COPD. The primary purpose of this study is to demonstrate improvements in lung function for subjects treated with UMEC/VI compared with UMEC for 24 weeks. Approximately 2424 subjects will be randomized across 3 parallel arms in 1:1:1 ratio. Subjects will be stratified based on long-acting bronchodilator usage during the run-in period (none, one or 2 long-acting bronchodilators per day). Subjects will receive either UMEC/VI inhalation powder (62.5/25 microgram \[mcg\] once daily) administered via the ELLIPTA® dry powder inhaler (DPI) and placebo twice daily via DISKUS® DPI; or UMEC (62.5 mcg once daily) administered via the ELLIPTA DPI and placebo twice daily via DISKUS DPI or salmeterol (50 mcg twice daily \[BID\]) administered via the DISKUS DPI and placebo once daily via ELLIPTA DPI. The duration of the study will be 29 to 31 weeks including a pre-screening period of 2 weeks, run-in period of 4 weeks, treatment period of 24 weeks and follow-up period of 1 week. ELLIPTA and DISKUS are trademarks of GSK group of companies.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI 62.5/25 mcg via ELLIPTADrug
ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
UMEC 62.5 mcg via ELLIPTADrug
The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
Salmeterol 50 mcg via DISKUSDrug
The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Placebo via ELLIPTADrug
Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
Placebo via DISKUSDrug
Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24Time frame: Baseline (Pre-dose on Day 1) and Week 24
Locations
212 sites in 12 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Lincoln, California
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
O'Fallon, Illinois
GSK Investigational Site
Natchitoches, Louisiana
GSK Investigational Site
Edina, Minnesota
GSK Investigational Site
Fridley, Minnesota
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Woodbury, Minnesota
GSK Investigational Site
Chesterfield, Missouri
GSK Investigational Site
Saint Charles, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Gastonia, North Carolina
GSK Investigational Site
Monroe, North Carolina
GSK Investigational Site
Mooresville, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Medford, Oregon
GSK Investigational Site
Anderson, South Carolina
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Easley, South Carolina
GSK Investigational Site
Gaffney, South Carolina
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Lancaster, South Carolina
GSK Investigational Site
Mt. Pleasant, South Carolina
GSK Investigational Site
Rock Hill, South Carolina
GSK Investigational Site
Seneca, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Union, South Carolina
GSK Investigational Site
Sherman, Texas
GSK Investigational Site
Abingdon, Virginia
GSK Investigational Site
Morgantown, West Virginia
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
Showing 40 of 212 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.